Additional file 1 of Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia
Creators: name: Wang, Jinghan
name: Pan, Jiajia
name: Huang, Shujuan
name: Li, Fenglin
name: Huang, Jiansong
name: Li, Xia
name: Ling, Qing
name: Ye, Wenle
name: Wang, Yungui
name: Yu, Wenjuan
name: Jin, Jie
Publisher: name: figshare
Year: 2021
Subjects: subject: Biophysics
subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Pharmacology
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Information Systems not elsewhere classified
subject: Cancer
subject: Hematology

description: Additional file 1: FigS1. [Distribution of propensity score analysis in 75 patients with the high quality of bone marrow samples]. FigS2. [Sequences inserted into pmirGLO reporter plasmid confirmed by Sanger sequencing]. FigS3. [Flowchart of constructing circRNA-miRNA-mRNA regulatory network]. FigS4. [Hazard ratios of altered hsa_circ_0075451 expression on overall survival by stratified analyses]. FigS5. [The predictive power of CircRNA (hsa_circ_0075451) and clinical and molecular factors]. FigS6. [Differentially expressed genes between high and low hsa_circ_0075451 expression]. FigS7. [In silico analysis of 15 miRNAs potentially interacted with hsa_circ_0075451 in the CircInteractome database]. FigS8. [Correlation relationship between hsa_circ_ 0075451 and microRNAs in 9 AML cell lines]. FigS9. [Dual luciferase reporter assays to test the interactive relationship between hsa_circ_0075451 and miRNAs]. FigS10. [Dual luciferase reporter assays to test the interactive relationship between 3’-UTR of PRMD16 and miRNAs]. FigS11. [ShRNA interference assay was used to further confirm the regulated relationship of hsa_circ_0075451 -| miR-326/ miR-330-5p -| PRDM16]. FigS12. [RNA FISH for hsa_circ_0075451(circGMDS) and miR-330-5p/miR-326 was detected in OCI-AML2 cells]. FigS13. [Metabolic changes in patients with aberrant hsa_circ_0075451 expression]. Table S1. [ Clinical characteristics of patients in the training group]. Table S2. [Primers of cRNA /miRNAs]. Table S3. [The sequences using for dual luciferase reporter assay]. Table S4. [Aberrantly expression of the circular RNA signatures between favorable and unfavorable group]. Table S5. [CircRNAs related to outcome validated by Cox regression analysis]. Table S6. [Gene Ontology and pathway analysis of survival associated circRNAs]. Table S7. [Different expression of circRNAs which encoding genes enriched in the GO:0016835 term]. Table S8. [Characteristics of CN-AML patients with high and low hsa_circ_0075451 expression in the validated cohort]. Table S9. [Landmark analysis of CN-AML patients]. Table S10. [Clinical characteristics of patients for mRNA profiling analysis]. Table S11. [mRNAs expression between high and low hsa_circ_0075451]. Table S12. [Gene enrichment analysis of the differentially expressed genes]. Table S13. [KEGG pathways and GO enrichment analyses in the 84 hub genes.]. Table S14. [Clinical characteristics of patients for the metabolomic analysis]. Table S15. [Pathways enriched analysis].